secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARVINAS, INC. (ARVN)
CIK:        0001655759
Form:       8-K
Filed at:   2025-11-05T23:59:59+00:00
Accession:  0001628280-25-049235
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arvinas Q3 cash $787.6M; vepdegestrant NDA accepted PDUFA June 2026
-------------------------------------------------------------------

- Cash and securities $787.6M at Sept 30, 2025, down from $1,039.4M at Dec 31, 2024; cash runway into H2 2028.
- R&D expenses $64.7M in Q3 2025 vs $86.9M in Q3 2024, down 26% YoY due to lower program costs.
- FDA accepted NDA for vepdegestrant in ER+/HER2- breast cancer; PDUFA date June 5, 2026.
- ARV-102 Phase 1 showed >90% LRRK2 reduction in PBMCs; no SAEs; multiple dose cohort launched in Parkinson's.
- Repurchased $17.8M of common shares under stock repurchase program in Q3 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1655759/000162828025049235/0001628280-25-049235-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1655759/000162828025049235/arvn-20251105.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-049235

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer